NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $45.00 price target on the stock.

Several other analysts have also commented on NRXP. D. Boral Capital reiterated a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, April 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. BTIG Research reiterated a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Zacks Research upgraded NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.25.

NRx Pharmaceuticals Stock Up 3.1%

NRx Pharmaceuticals stock opened at $3.03 on Monday. NRx Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.84. The business has a fifty day moving average of $2.15 and a two-hundred day moving average of $2.33. The firm has a market cap of $100.20 million, a P/E ratio of -2.18 and a beta of 1.83.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Monday, March 23rd. The company reported $0.19 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.28. The business had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $7.53 million. Equities analysts expect that NRx Pharmaceuticals will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 26.2% during the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock worth $6,683,000 after purchasing an additional 420,129 shares during the period. AdvisorShares Investments LLC grew its position in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares during the period. One Wealth Management Investment & Advisory Services LLC grew its position in NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares during the period. Ethos Financial Group LLC acquired a new stake in NRx Pharmaceuticals during the 3rd quarter worth about $39,000. Finally, Commonwealth Equity Services LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth about $994,000. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.